Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Lexaria Bioscience Corp.

< Previous 1 2 Next >
News headline image
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes
From Lexaria Bioscience Corp.
Via AccessWire
Topics Death Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria's Technology Proven to Deliver Oral THC More Effectively
From Lexaria Bioscience Corp.
Via AccessWire
Topics Cannabis Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria's DehydraTECH-CBD Lowers Blood Pressure
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property Supply Chain
Tickers LEXX LEXXW
News headline image
Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria Receives US$3,817,643 From Warrant Exercises
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
From Lexaria Bioscience Corp.
Via AccessWire
Topics Animal Testing Death Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
From Lexaria Bioscience Corp.
Via AccessWire
Topics Animal Testing Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria Receives Patent Protection in Japan
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria Announces 2021 Annual Meeting Results
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria Provides Progress Report on Six R&D Programs
From Lexaria Bioscience Corp.
Via AccessWire
Topics Animal Testing Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever
From Lexaria Bioscience Corp.
Via AccessWire
Topics Animal Testing Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ET
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.